

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/009848 A1

(51) International Patent Classification: **A61K 31/46,**
31/4418, A61P 25/22

(US). **KILROY, Carolyn, Rose** [US/US]; Pfizer Global
Research and Development, Eastern Point Road, Groton,
CT 06340 (US).

(21) International Application Number: **PCT/IB02/02847**

(74) Agents: **LUMB, J., Trevor et al.**; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(22) International Filing Date: **15 July 2002 (15.07.2002)**

(25) Filing Language: **English**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(26) Publication Language: **English**

(30) Priority Data:
60/306,692 **20 July 2001 (20.07.2001)** **US**

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US **60/306,692 (CON)**
Filed on **20 July 2001 (20.07.2001)**

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PFIZER
PRODUCTS INC.** [US/US]; Eastern Point Road, Groton,
CT 06340 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BRONK, Brian,**
Scott [US/US]; Pfizer Global Research and Development,
Eastern Point Road, Groton, CT 06340 (US). **HICK-**
MAN, Mary, Anne [US/US]; Pfizer Global Research
and Development, Eastern Point Road, Groton, CT 06340

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND
HORSES**

(57) Abstract: The present invention relates to a method of treating abnormal anxiety behavior in companion animals comprising
administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.

WO 03/009848 A1

Best Available Copy

-1-

USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS,
CATS AND HORSES

BACKGROUND OF THE INVENTION

Anxiety behaviors in companion animals can be devastating conditions that, in the
5 absence of treatment, may result in relinquishment to a humane society or shelter,
abandonment, or euthanasia. For example, a study of dogs in animal shelters in the
Netherlands showed that 50% of dogs that found new homes were returned to a shelter. See
J. van der Borg, W. J. Netto and D.J. Planta, "Behavioural Testing of Dogs in Animal Shelters
to Predict Problem Behavior," Applied Animal Behaviour Science 32 (1991), pp. 237-251.
10 One frequently cited reason for returning a dog was behavior attributed to separation anxiety.

Anxiety behaviors can be common disorders in some species of companion animals.
For example, it has been estimated that in the average veterinary practice in the US up to
14% of canine patients exhibit one or more signs of separation anxiety. K. Overall,
"Understanding Canine Separation Anxiety." Elimination, destruction, and vocalization are
15 the most commonly reported behaviors associated with separation anxiety. Id. Other
behaviors associated with anxiety include salivation, anorexia, and lethargy. Id.

Excessive barking is a recognized behavior problem in dogs. Soraya Juarbe-Diaz
has suggested treating excessive barking by limited use of psychotropic medication after a
thorough patient evaluation. S. Juarbe-Diaz, "Assessment and Treatment of Excessive
20 Barking in the Domestic Dog," Progress in Companion Animal Behavior 27 (May 1997), pp.
515-532. Juarbe-Diaz recommends the following psychoactive drugs as adjuncts to behavior
modification in the treatment of selected cases of nuisance barking: amitriptyline, buspirone,
clomipramine, and fluoxetine. Id.

It is desirable to provide a pharmaceutical therapy to treat abnormal anxiety
25 behaviors in companion animals and thereby to allow the afflicted animal to remain in its
owner's home or as a pet.

To develop a pharmaceutical therapy to treat abnormal anxiety behaviors, it is
advantageous to have an accurate, reproducible, and safe method for evaluating whether a
test compound has anxiolytic activity. Angels et al. studied human avoidance as a measure of
30 drug effects on nervous pointer dogs. Angels et al., "Assessment of Pointer Dog Behavior,"
Pav. J. Biol. Sci. 17 (April-June 1982), pp. 84-88. Angels et al. describe a "Human Interaction
Test" in which positive and negative scores are assigned to different behaviors involving
interaction with humans. Van der Borg et al. teach a set of behavioral tests to be
administered to dogs in shelters to improve the matching between dog and future owner. Van
35 der Borg et al., at 237.

The tachykinins, substance P, neurokinin A and neurokinin B are structurally similar members of a family of neuropeptides that is believed to be involved in anxiety behaviors in mammals. The involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has
5 been shown to be involved in the transmission of pain or migraine (see B. E. B. Sandberg et al., J. Med. Chem. 25 (1982) 1009), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, in rheumatic diseases such as fibrositis, and in gastrointestinal disorders and diseases of the GI tract such as ulcerative colitis and Crohn's
10 disease, etc. (see D. Regoli in "Trends in Cluster Headache," edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, pp. 85-95 (1987)).

Substance P is known to bind to the neurokinin 1 (NK-1) receptor. NK-1 receptors have been isolated and characterized.

NK-1 receptor antagonists are being developed for the treatment of disorders
15 associated with an excess or imbalance of tachykinins, and particularly of substance P. For example, WO99/07375 discloses the use of NK-1 receptor antagonists for the treatment or prevention of aggressive behavior. US Patent No. 6,117,855 and WO 98/15277 disclose combination therapy of an NK-1 receptor antagonist and an anti-depressant or anti-anxiety agent to treat anxiety or depression. Specific tachykinin receptor antagonists are described in
20 WO 96/10568 for the treatment of a multitude of disorders, including anxiety, depression, psychosis and schizophrenia. Similarly, WO 00/35915 discloses piperazine derivatives to treat tachykinin-mediated diseases such as anxiety disorders. Other NK-1 receptor antagonists are identified in U.S. Patent No. 5,773,450, "Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles," issued June 30, 1998 and U.S. Patent No. 6,222,038,
25 "Quinuclidine derivatives," issued April 24, 2001. All patents, articles and other references referred to herein are hereby incorporated herein in their entireties.

Although many NK-1 receptor antagonists have been described and their usefulness to treat tachykinin-related disorders including anxiety has been asserted, disclosure of specific behaviors in companion animals that can be altered by administration of an NK-1
30 receptor antagonist is not believed to have been provided heretofore.

An object of the invention is to provide a pharmaceutical therapy for companion animals to reduce or prevent unwanted behaviors associated with NK-1 receptor activity. Another object of the present invention is to provide a pharmaceutical therapy for companion animals to treat abnormal anxiety behaviors.

35 Another object of the present invention is to provide a pharmaceutical therapy for companion animals to treat one or more of the following behaviors: abnormal vocalization

(barking, crying, growling, howling and whining); hyperactivity (jumping, pacing, circling, increased inquisitiveness, hypervigilance, and tremors); destruction (chewing, digging, and escape behaviors); abnormal sleep (disrupted sleep, insomnia, and increased sleep); abnormal feeding (anorexia, dysorexia, polyphagia, and obesity); abnormal drinking
5 (polydipsia); abnormal grooming (excessive licking, chewing, and nibbling); abnormal elimination (vomiting, diarrhea, and polyuria); abnormal fears and phobias (loud noises, fireworks, and thunder); and socialization disorders (fear of strangers, dogs and selected objects).

Another object of the present invention is to provide a method of screening a test
10 compound to determine anxiolytic activity in dogs.

SUMMARY OF THE INVENTION

The present invention relates to a method of treating abnormal anxiety behavior in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.

15 The present invention relates to a method of treating abnormal anxiety behavior in a companion animal in which the method comprises evaluating the companion animal for the exhibition of an abnormal anxiety behavior, determining that the companion animal exhibits the abnormal anxiety behavior and thus is in need of treatment, and administering to the companion animal a therapeutically effective amount of an NK-1 receptor antagonist for a
20 time sufficient to reduce or eliminate the abnormal anxiety behavior.

The present invention also provides for the use of an NK-1 receptor antagonist in the manufacture of a medicament for the treatment of abnormal anxiety behavior in companion animals.

The present invention also provides a method of screening a test compound to
25 determine anxiolytic activity in dogs comprising (a) selecting a dog exhibiting anxiety behavior; (b) administering the test compound to the dog; (c) separating the dog from views of other dogs and of humans; (d) measuring a first duration of time, the first duration of time being the time within a separation period of a fixed duration during which the anxiety behavior is exhibited; and (e) comparing the first duration of time with a second duration of time,
30 wherein the second duration of time is the time within a separation period of the fixed duration that the anxiety behavior is exhibited in the dog when the dog has not received the test compound for at least forty-eight hours. If the first duration of time is less than the second duration of time, the test compound is determined to have anxiolytic activity.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of treating abnormal anxiety behavior such as vocalization, hyperactivity, destruction, abnormal sleep, abnormal feeding, abnormal drinking, abnormal grooming, abnormal elimination, abnormal fears and phobias, and socialization disorders in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.

Preferably, the invention is directed to a method of treating vocalization, hyperactivity, destruction, abnormal feeding, and abnormal elimination in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.

More preferably, the invention is directed to a method of treating vocalization, hyperactivity, and destruction in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.

The methods of treatment of the present invention are administered to animals in need thereof. Such animals have exhibited one or more abnormal anxiety behaviors, have been evaluated or diagnosed as exhibiting this behavior, are in need of treatment to reduce or eliminate this behavior, and are treated at a dosage and for a period of time sufficient to reduce or eliminate this behavior.

As used herein, the term "treat" means to reduce or eliminate undesirable behaviors in a patient in need thereof.

As used herein, the term "companion animal" includes dogs, cats, and horses, and preferably is a dog.

The NK-1 receptor antagonist is preferably selected from the group consisting of:

(2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine;

(2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;

(2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;

(2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;

(2S,3S)-3-(5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;

2-(diphenylmethyl)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-1-azabicyclo[2.2.2]octan-3-amine;

(2S,3S)-3-[5-chloro-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;

(2S,3S)-3-(5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;

- (2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-difluoromethoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
(2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxybenzyl)-aminopiperidine];
(2S,3S)-2-phenyl-3-(2-trifluoromethoxybenzyl)aminopiperidine;
5. cis-3-(2-chlorobenzylamino)-2-phenylpiperidine;
cis-3-(2-trifluoromethylbenzylamino)-2-phenylpiperidine;
cis-3-(2-methoxybenzylamino)-2-(2-fluorophenyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-(2-chlorophenyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-(2-methylphenyl)piperidine;
- 10 cis-3-(2-methoxybenzylamino)-2-(3-methoxyphenyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-fluorophenyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-chlorophenyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-phenylpiperidine;
cis-3-(2-methoxybenzylamino)-2-(3-methylphenyl)piperidine;
- 15 cis-3-(2-methoxybenzylamino)-2-(4-fluorophenyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-thienyl)piperidine;
cis-3-(2-methoxybenzylamino)-2-phenylazacycloheptane;
3-(2-methoxybenzylamino)-4-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-5-methyl-2-phenylpiperidine;
- 20 3-(2-methoxybenzylamino)-6-methyl-2-phenylpiperidine;
(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5-carboethoxypent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(6-hydroxyhex-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(4-hydroxy-4-phenylbut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
- 25 (2S,3S)-1-(4-oxo-4-phenylbut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5,6-dihydroxyhex-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
cis-3-(5-fluoro-2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-3-(2-methoxybenzylamino)-2-phenylpiperidine;

- (2S,3S)-1-[4-[4-fluorophenyl]-4-hydroxybut-1-yl]-3-(2-methoxybenzylamino)-2-phenylpiperidine;
- cis-3-(2-methoxy-5-methylbenzylamino)-2-phenyl-piperidine;
- (2S,3S)-1-(4-benzamidobut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
- 5 cis-3-(2-methoxynaphth-1-ylmethylamino)-2-phenyl-piperidine;
- (2S,3S)-3-(2-methoxybenzylamino)-1-(5-N-methyl-carboxamidopent-1-yl)-2-phenylpiperidine;
- (2S,3S)-1-(4-cyanobut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
- (2S,3S)-1-[4-(2-naphthamido)but-1-yl]-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
- (2S,3S)-1-(5-benzamidopent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
- 10 (2S,3S)-1-(5-aminopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
- (2S,3S)-3-(5-chloro-2-methoxybenzylamino)-2-phenyl-piperidine;
- (2S,3S)-3-(2,5-dimethoxybenzylamino)-2-phenyl-piperidine;
- cis-3-(3,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
- cis-3-(4,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
- 15 cis-3-(2,5-dimethoxybenzylamino)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-2-phenylpiperidine;
- cis-3-(5-chloro-2-methoxybenzylamino)-1-(5,6-dihydroxyhex-1-yl)-2-phenylpiperidine;
- cis-1-(5,6-dihydroxyhex-1-yl)-3-(2,5-dimethoxy-benzylamino)-2-phenylpiperidine;
- cis-2-phenyl-3-[2(prop-2-yloxy)benzylamino]piperidine;
- cis-3-(2,5-dimethoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine hydro-
- 20 chloride;
- cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine dihydrochloride;
- cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-chloro-phenyl)piperidine dihydrochloride;
- 3-(2-methoxybenzylamino)-2,4-diphenylpiperidine;
- cis-3-(2-methoxybenzylamino)-2-phenylpyrrolidine;
- 25 (2S,3S)-3-(5-ethyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
- (2S,3S)-3-(5-n-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
- (2S,3S)-3-(2-methoxy-5-n-propylbenzyl)amino-2-phenyl-piperidine;
- (2S,3S)-3-(5-isopropyl-2-methoxybenzyl)amino-2-phenyl-piperidine;

- (2S,3S)-3-(5-s-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
 (2S,3S)-3-(5-t-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
 (2S,3S)-3-(2-methoxy-5-phenylbenzyl)amino-2-phenyl-piperidine;
 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methylamide;
 5 N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanesulfonamide;
 (5-((4,5-dimethylthiazol-2-yl)methylamino)-2-methoxybenzyl)-((2S,3S)-2-phenylpiperidin-3-yl)amine;
 10 (5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl)-((2S,3S)-2-phenylpiperidin-3-yl)amine;
 4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3-ylamino-methyl)-4-trifluoromethoxyphenyl]-amide;
 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methylamide;
 15 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isopropylamide;
 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isopropylamide;
 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isobutylamide;
 20 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isobutylamide;
 (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
 25 (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
 (2S,3S)-N-(5-methyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
 (2S,3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
 30

- (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (2S,3S)-N-(5-sec-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- 5 (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (3R,4S,5S,6S)-N,N-diethyl-5-(5-isopropyl-2-methoxy-benzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxamide;
- (3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxamide;
- 10 (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 15 (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 20 (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 25 (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxy-benzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 30 (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;


- (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 5 (3R,4S,5S,6S)-5-(2-methoxy-5-methylthiobenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 10 (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 15 (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 20 (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid; and
- 25 (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- and the pharmaceutically acceptable salts of the foregoing compounds.

The following references refer, collectively, to quinuclidine, piperidine, ethylene diamine, pyrrolidine and azanorbomane derivatives and related compounds that exhibit activity as NK-1 receptor antagonists which can be used in the pharmaceutical methods of this invention: United States Patent 5,162,339, which issued on November 11, 1992; United States Patent 5,232,929, which issued on August 3, 1993; World Patent Application WO


92/20676, published November 26, 1992; World Patent Application WO 93/00331, published January 7, 1993; World Patent Application WO 92/21677, published December 10, 1992; World Patent Application WO 93/00330, published January 7, 1993; World Patent Application WO 93/06099, published April 1, 1993; World Patent Application WO 93/10073, published May 27, 1993; World Patent Application WO 92/06079, published April 16, 1992; World Patent Application WO 92/12151, published July 23, 1992; World Patent Application WO 92/15585, published September 17, 1992; World Patent Application WO 93/10073, published May 27, 1993; World Patent Application WO 93/19064, published September 30, 1993; World Patent Application WO 94/08997, published April 28, 1994; World Patent Application WO 94/04496, published March 3, 1994; World Patent Application WO 94/13663, published June 23, 1994; World Patent Application WO 94/20500, published September 15, 1994; World Patent Application PCT/IB94/00221, filed on July 18, 1994; World Patent Application PCT/JP94/00781, filed on May 13, 1994; World Patent Application PCT/JP94/01092, filed on July 5, 1994; and World Patent Application PCT/JP94/01514, filed on September 13, 1994; United States Patent Application 988,653, filed December 10, 1992; United States Patent Application 026,382, filed March 4, 1993; United States Patent Application 123,306, filed September 17, 1993, and United States Patent Application 072,629, filed June 4, 1993. The foregoing patents and patent applications are incorporated herein by reference in their entirety.

Other NK-1 receptor antagonists that can be used in the pharmaceutical methods of this invention are those compounds and pharmaceutically acceptable salts described in the following references: European Patent Application EP 499,313, published August 19, 1992; European Patent Application EP 520,555, published December 30, 1992; European Patent Application EP 522,808, published January 13, 1993, European Patent Application EP 528,495, published February 24, 1993, PCT Patent Application WO 93/14084, published July 22, 1993, PCT Patent Application WO 93/01169, published January 21, 1993, PCT Patent Application WO 93/01165, published January 21, 1993, PCT Patent Application WO 93/01159, published January 21, 1993, PCT Patent Application WO 92/20681, published November 26, 1992, European Patent Application EP 517,589, published December 12, 1992, European Patent Application EP 428,434, published May 22, 1991, and European Patent Application EP 360,390, published March 28, 1990; PCT Patent Application WO 95/04042, published February 9, 1995, PCT Patent Application WO 95/08549, published March 30, 1995, PCT Patent Application WO 95/19344, published July 20, 1995, PCT Patent Application WO 95/23810, published September 8, 1995, and PCT Patent Application WO 95/20575, published August 3, 1995. These publications are also incorporated herein by reference in their entireties.

More preferably, the NK-1 receptor antagonist is a compound of Formula 1, Formula 2 or a pharmaceutically acceptable salt thereof.



Formula 1 (2S,3S) (2-Benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-tert-butyl-2-methoxy-benzyl)-amine



Formula 2 (2S,3S)(2-Methoxy-5-trifluoromethoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine)

The NK-1 receptor antagonists used in the present invention may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to uses for all optical isomers and all stereoisomers of compounds of the Formula 1 or Formula 2 and mixtures thereof.

The NK-1 receptor antagonist should be chosen from CNS-penetrant NK-1 receptor antagonists. It is well known to those in the art how to determine if an NK-1 receptor antagonist is CNS penetrant. For example, tests are disclosed in WO 98/15277.

NK-1 receptor antagonist includes compounds that have an NK-1 receptor affinity (IC_{50}) of less than 100nM. Preferably, the NK-1 receptor antagonist has IC_{50} #10nM, and more preferably IC_{50} # 1nM.

To determine NK-1 receptor affinity, one of the NK-1 receptor binding assays well known in the art may be used. One such assay is described by Cascieri et al., J. Pharmacol. Exp. Ther., 1992, 42, 458.

It is understood that the amino acid sequence of the NK-1 receptor may differ between species. Accordingly, the assay for NK-1 receptor binding preferably involves an NK-1 receptor naturally occurring in the species of companion animal to be treated. However, it is within the skill of one in the art to determine if the binding results from an assay in which an NK-1 receptor from a different species is used are sufficient to predict with reasonable certainty NK-1 receptor binding in the species to be treated.

The NK-1 receptor antagonists can be administered via oral, parenteral, inhalation or topical routes, preferably orally.

To determine an efficacious dosage, multiple complete cross-over studies can be performed with the NK-1 receptor antagonist in the species of companion animal to be treated at various doses. The optimal dose is selected based on the maximal ability to decrease the time spent in abnormal behaviors.

For example, non-peptidyl NK-1 receptor antagonists are most desirably administered in dosages ranging from about 0.01 mg/kg animal body weight to about 5 mg/kg animal body weight per dosage, preferably in dosages of from about 0.1 mg/kg to 0.3 mg/kg. The dosage is administered from once to six times per day, and preferably is administered once or twice a day. Peptidyl NK-1 receptor antagonists are preferably administered parenterally or through inhalation, in dosages readily determinable by those of skill in the art.

Duration of therapy may vary depending on the animal's condition. Duration of therapy can be for two to four months when administered concurrent with behavioral therapy to reduce or eliminate the abnormal anxiety behavior. After acceptable alternative behavior is maintained for four to six weeks, the animal can be weaned off of the medication. In some instances, lifelong medication may be needed to maintain acceptable behavior. Administration should occur at least until the abnormal behavior is reduced to an acceptable level.

Dosages can be determined by dose titration as is known to those skilled in the art. An example of a dose titration for (2S,3S)(2-Benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-tert-butyl-2-methoxy-benzyl)-amine is provided in the examples that follow.

Variations may occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than

adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

The NK-1 receptor antagonists used in the invention may be administered alone or in
5 combination with pharmaceutically acceptable carriers or diluents by any of the routes
previously indicated, and such administration may be carried out in single or multiple doses.
More particularly, the novel therapeutic agents of this invention can be administered in a wide
variety of different dosage forms, i.e., they may be combined with various pharmaceutically
acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies,
10 powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments,
aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include
solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In
general, the therapeutically-effective compounds of this invention are present in such dosage
15 forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline
cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be
employed along with various disintegrants such as starch (and preferably corn, potato or
tapioca starch), alginic acid and certain complex silicates, together with granulation binders
20 like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as
magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting
purposes. Solid compositions of a similar type may also be employed as fillers in gelatin
capsules; preferred materials in this connection also include lactose or milk sugar as well as
high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are
25 desired for oral administration, the active ingredient may be combined with various
sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or
suspending agents as well, together with such diluents as water, ethanol, propylene glycol,
glycerin and various like combinations thereof.

For parenteral administration, solutions of a therapeutic compound of the present
30 invention in either sesame or peanut oil or in aqueous propylene glycol may be employed.
The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary
and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for
intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular
and subcutaneous injection purposes. The preparation of all these solutions under sterile
35 conditions is readily accomplished by standard pharmaceutical techniques well known to
those skilled in the art.

The method of treatment of the present invention also may be combined with other treatment therapies, and particularly with other therapies directed to treating abnormal aggressive behaviors or abnormal anxiety behaviors. For example, the administration of an NK-1 receptor antagonist to a companion animal to treat abnormal anxiety behaviors may be
5 combined with the administration of tricyclic antidepressants such as clomipramine and amitriptyline, the administration of agents that act as serotonin, norepinephrine and/or dopamine reuptake inhibitors, including venlafaxine; sedative agents such as benzodiazepenes (including Diazepam®) and phenothiazines (including Acepromazine®), and/or the administration of selective serotonin reuptake inhibitors, such as fluoxetine
10 hydrochloride (sold under the tradename Prozac®) and sertraline hydrochloride (sold under the tradename Zoloft®).

Preferably, the methods of treatment of the present invention are combined with concurrent behavior modification training. An example of one behavior modification training is desensitization by exposing the animal to arousing stimuli at a level that does not evoke a
15 response and then rewarding the animal for staying calm.

Canine Anxiety Model:

The present invention also concerns a method for testing compounds for anxiolytic effect in dogs. The model is designed to induce separation anxiety as well as anxiety due to novel visual and auditory stimuli. To determine whether a test compound has an anxiolytic
20 effect in dogs, separation anxiety and anxiety associated with novel sight and sound stimuli are measured both with and without administration of the test compound.

In one preferred embodiment, observations are made on five different anxiety behaviors during a 15-minute separation phase and a 15-minute stimulation phase. These anxiety behaviors are vocalization (barking, crying, growling); hyperactivity (jumping, pacing,
25 circling); destruction (chewing, pawing, digging); salivation; and tremor. The duration of time (in seconds) that each behavior is exhibited is recorded and totaled at the end of each 15-minute phase. In addition to direct observation, dogs are videotaped during testing for documentation of behaviors.

In one preferred embodiment, a dog is removed from a group pen and placed in an isolation cage. A tester, positioned behind a screen out of view, starts a timer for 15 minutes
30 and a video recorder. The duration of time (in seconds) an individual animal exhibits each behavior is recorded. At the end of the separation phase, the timer is re-set to 15 minutes and a child-size doll mounted on a remote controlled car is driven around the pen continuously. After 10 minutes, the doll and car are driven behind the screen and a child's
35 fazez gun with a variety of sounds is continually activated for 5 minutes. At the end of the

-15-

stimulation phase, the accumulated time for each behavior is recorded and the video recorder stopped. The dog is removed from the isolation cage and returned to the group pen.

Preferably, a complete cross-over study design with test compound and placebo is used. Each treatment period is 21 days in length. Study "day 0" is used to designate the initial day of dosing. Anxiety testing is conducted on study days 6 and 20 within each period. Animals are allocated to treatment group, sequence, pen and evaluation order using a randomization plan. Dogs remain within the same sequence during progression of the cross-over phases of the study so that all possible treatment orders are evenly represented. Preferably, "day 0" is staggered such that 3-6 dogs are evaluated per day. Treatment administration is adjusted on testing days such that each animal is tested at the predicted Cmax for the test compound. Anxiety testing is preferably conducted between 11AM and 4 PM to account for time-of-day variations in behavior. Animals are fed at the conclusion of testing. A three-week washout is observed between periods.

Selection of Study Candidates:

Preferably, dogs that have previously displayed symptoms of separation anxiety are used in this model. A screening model is used in the selection of study candidates. For example, a dog is removed from a group pen and placed alone in a cage in an adjacent room. An observer stands behind a one-way glass and observes the dog for the following behaviors: excessive vocalization (barking, crying, howling), hyperactivity (pacing, circling, jumping) and destructive behaviors (digging, chewing, pawing). The dog is observed for 10 minutes. If no anxious behavior is observed, the dog is returned to the pool. Dogs exhibiting anxious behaviors are screened once weekly for 4 weeks. If the behaviors are repeated and consistent, the dog moves on to the next selection period. The dog is challenged in the separation phase of the canine anxiety model once weekly for six weeks. Preferably, the study only uses dogs that have exhibited anxiety each week during the six weeks of screening.

It is envisioned that the method of testing compounds for anxiolytic behavior in dogs may be altered from the preferred embodiment as would be evident to one skilled in the art. For example, the separation period of a fixed duration during which behaviors are observed may be fifteen minutes, as described in the preferred embodiment, or may be any other time period of or predetermined duration that allows sufficient time to observe behaviors such that distinctions may be drawn between behavior with or without administration of the test compound.

The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these examples.

EXAMPLE 1

To evaluate the anxiolytic effects of a compound of Formula 1 vs. placebo after seven and twenty-one days of parenteral dosing at 0.1 mg/kg SID, the following procedure was followed.

5 **Test Materials:**

Compound of Formula 1		Placebo	
Dosage form	Subcutaneous Injection	Dosage form	Subcutaneous
Potency	69%	Potency	0%
10 Formulation	Dissolved in 20% (w/v) SBE SBE cyclodextrin in water to make a cyclodextrin in base equivalent solution in water of 5 mg/ml	Formulation	20% (w/v) water

15 **Study Design:**

Adult dogs with spontaneous anxiety to isolation and/or unfamiliar humans were treated for twenty-one consecutive days with the compound of Formula 1 or a placebo control. Dogs were tested after seven and twenty-one days of dosing. "Day 0" was used to identify the initial day of dosing. The study was conducted using a double-blind crossover design. Treatment periods were 21 days in duration, with a 28 day washout period between treatments. Dogs were randomly assigned to treatment groups such that those receiving compound at the first replicate received placebo on the second replicate. The placebo treatments served as the negative control.

25 All study participants were blinded to treatment groups. The compound of Formula 1 was administered at a dose of 0.1 mg/kg. The volume of vehicle control used for the placebo treatments was equivalent to the calculated volume of test compound that would have been administered had the animal been receiving drug. All test articles were administered by subcutaneous injection once daily.

Behavior Analysis:

30 On the day of testing, each dog was placed in a cage in an isolated room for 15 minutes. A hidden observer timed any anxious behavior. Animals were tested on dosing day 6 and day 20, starting 2 hours after the dose of the day.

Abnormal anxiety behaviors were studied. Observations were made on two different anxiety behaviors during a 15-minute separation phase. These behaviors are vocalization (barking, crying, growling) and hyperactivity (jumping, pacing, circling). The duration of time

-17-

(in seconds) that each behavior was exhibited was measured using a remote data capture device and totaled for each animal at the end of each 15 minute period.

Results:

5 The following table (Table 1) summarizes the mean data from dogs included in the experiment.

Table 1
The Compound of Formula 1 @ 0.1 mg/kg Vs. Placebo
Geometric Mean Time (seconds)
Separation Phase

10

		Vocalization	Hyperactivity
<i>Treatment</i>	<i>Day of Study</i>	<i>Mean</i>	<i>Mean</i>
Placebo	Day 6	36.1	25.8
Formula 2	Day 6	29.0	24.1
Placebo	Day 20	53.1	42.5
Formula 2	Day 20	25.5	19.1

As is evident from the data in Table 1, the NK-1 receptor antagonist of Formula 1 is more effective than placebo at treating vocalization and hyperactivity resulting from separation.

15

EXAMPLE 2

Various dosages of the compound of Formula 1 were tested to determine an optimal dose. Anxiety associated with separation and with novel sight and sound stimuli was measured.

20 Observations are made on two different anxiety behaviors during a 15-minute separation phase and a 15-minute stimulation phase. These behaviors are vocalization (barking, crying, growling) and hyperactivity (jumping, pacing, circling). The duration of time (in seconds) that each behavior is exhibited is recorded and totaled at the end of each 15-minute phase. In addition to direct observation, dogs are videotaped during testing for documentation of behaviors.

25 The dog is removed from a group pen and placed in an isolation cage in an adjacent room. The tester, positioned behind a screen out of view, starts a timer for 15 minutes and the video recorder. The duration of time (in seconds) that an individual animal exhibits each behavior is recorded. At the end of the separation phase, the timer is re-set to 15 minutes and a child-size doll mounted on a remote controlled car is driven around the pen continuously.

30 After 10 minutes, the doll and car are driven behind the screen and a child's fuzzer gun with a

variety of sounds is continually activated for 5 minutes. At the end of the stimulation phase, the accumulated time for each behavior is recorded and the video recorder stopped. The dog is removed from the isolation cage and returned to the group pen.

5

Table 2.
Compound of Formula 1 @ 1mg/kg Vs. Placebo
Geometric Mean Time (second)
"Comp. 1" is a Compound of Formula 1

Separation Phase		Vocalization	Hyperactivity
Treatment	Study Day	Mean	Mean
Comp. 1	Day 6	5.8	23.3
Placebo	Day 6	7.9	15.0
Comp. 1	Day 20	6.9	16.8
Placebo	Day 20	8.5	17.0
Stimulation Phase		Vocalization	Hyperactivity
Comp. 1	Day 6	6.5	22.7
Placebo	Day 6	8.9	28.8
Comp. 1	Day 20	7.4	36.0
Placebo	Day 20	7.3	20.9

10

Table 3.
Compound of Formula 1 @ 0.3mg/kg Vs. Day -1
Geometric Mean Time (second)

		Vocalization	Hyperactivity
Phase	Study Day	Mean	Mean
Separation	Day -1	31.8	71.4
Separation	Day 6	20.9	49.7
Separation	Day 20	18.2	39.1
Stimulation	Day -1	33.4	104.9
Stimulation	Day 6	15.9	43.1
Stimulation	Day 20	19.2	41.9

-19-

5

Table 4.
Compound of Formula 1 @ 0.1mg/kg Vs. Day -1
Geometric Mean Time (second)

		Vocalization	Hyperactivity
Phase	Study Day	Mean	Mean
Separation	Day -1	35.9	47.2
Separation	Day 6	15.5	24.7
Separation	Day 20	9.1	14.8
Stimulation	Day -1	48.9	70.9
Stimulation	Day 6	36.8	48.8
Stimulation	Day 20	24.7	28.4

10

Table 5.
Compound of Formula 1 @ 0.03 mg/kg Vs. Day -1
Geometric Mean Time (second)

		Vocalization	Hyperactivity
Phase	Study Day	Mean	Mean
Separation	Day -1	22.1	46.0
Separation	Day 6	10.6	19.4
Separation	Day 20	12.1	20.1
Stimulation	Day -1	38.6	54.9
Stimulation	Day 6	24.5	38.6
Stimulation	Day 20	35.6	28.2

15

Table 6.
Compound of Formula 1 @ 0.1mg/kg Vs. Placebo
Geometric Mean Time (second)

Separation Phase		Vocalization	Hyperactivity
Treatment	Study Day	Mean	Mean
Comp. 1	Day 6	29.0	24.1
Placebo	Day 6	36.1	25.8
Comp. 1	Day 20	25.5	19.1
Placebo	Day 20	53.1	42.5

Stimulation Phase		Vocalization	Hyperactivity
Comp. 1	Day 6	35.3	46.7
Placebo	Day 6	46.7	47.2
Comp. 1	Day 20	26.4	51.2
Placebo	Day 20	56.2	69.6

Tables 3-5 refer to "Day -1" which is the day prior to initial dosage. The data shows that among those dosages tested, the most efficacious dosage in dogs of the compound of Formula 1 is 0.1 mg/kg SC.

5

EXAMPLE 3

Adult dogs received ten consecutive oral doses of a compound of Formula 2 at 5 mg/kg BID or placebo in a cross-over design and effects on behavior were determined beginning one-hour post-dose.

Materials:

- 10 Compound Compound of Formula 2
- Dosage form Oral capsule
- Potency capsules at 5 mg/kg activity

Management:

- 15 Water: ad libitum
- Feed: Standard high energy canine ration
- Feed at 1300, remove food at 1500

Methods:**Preparation of dose:**

- 20 Appropriate amounts of the compound of Formula 2 were weighed and placed in capsules. Capsules were back-filled with dextrose.

Administration of dose:

Capsules were administered by placing them in the back of the throat and allowing the dogs to swallow. On the day of behavior testing, dogs were fasting at dosing.

Design:

- Dogs were divided equally into two treatment groups. Treatment Group 1 received 10 consecutive oral doses of the compound of Formula 2 BID at 5 mg/kg and Treatment Group 2 received 10 consecutive oral dextrose placebos BID. At the conclusion of the first half of the study, the protocol was repeated and dogs in Treatment Group 1 received 10 consecutive oral dextrose placebos BID and dogs in Treatment Group 2 received 10 consecutive oral doses of the compound of Formula 2 BID at 5 mg/kg.

Behavior assessment:

- Dogs began compound dosing at 1830 and continued for 10 consecutive BID doses. The final dose (dose #10) occurred the morning of testing, one hour prior to the start. Dogs were tested in three 15-minute testing phases in which behavior was scored every 5 minutes. Dogs were videotaped during the testing period.

Table 7
Effect of Multi-dose compound of Formula 2@ 5 mg/kg on Behavior Scores* in Dogs
*Estimated duration of time in seconds

Dog ID	Separation Vocalization 0-15 min		Separation Hyperactivity 0-15 min	
	Placebo	Comp. 2	Placebo	Comp. 2
219622	42	22	50	30
70954	2	0	4	2
234923	6	0	6	2
HIHMFU	0	0	50	12
240893	4	0	6	6
215155	14	12	6	2
227641	6	2	2	2
2943450	90	30	36	18
Mean	20.5	8.25	20.0	9.25

Score System:

Converted original score of 1,2,3 to estimated time in seconds

20

1 = 2 seconds

2 = 10 seconds

3 = 30 seconds

CLAIMS

1. A method of treating abnormal anxiety behavior in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.
- 5 2. The method of claim 1, wherein the abnormal anxiety behavior is selected from the group consisting of vocalization, hyperactivity, destruction, abnormal sleep, abnormal feeding, abnormal drinking, abnormal grooming, abnormal elimination, abnormal fears and phobias, and socialization disorders.
3. The method of claim 1, wherein the companion animal is selected from the group consisting of dogs, cats, and horses:
- 10 4. The method of claim 1, wherein the NK-1 receptor antagonist is selected from the group consisting of:
 - (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxy-phenyl)piperidine;
 - 15 (2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine;
 - (2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine;
 - (2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
 - (2S,3S)-3-(5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
 - 20 2-(diphenylmethyl)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-1-azabicyclo[2.2.2]octan-3-amine;
 - (2S,3S)-3-[5-chloro-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
 - (2S,3S)-3-(5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
 - (2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
 - (2S,3S)-3-(2-difluoromethoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
 - 25 (2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxybenzyl)-aminopiperidine];
 - (2S,3S)-2-phenyl-3-(2-trifluoromethoxybenzyl)]aminopi-peridine;
 - cis-3-(2-chlorobenzylamino)-2-phenylpiperidine;
 - cis-3-(2-trifluoromethylbenzylamino)-2-phenyl- piperidine;
 - cis-3-(2-methoxybenzylamino)-2-(2-fluorophenyl)- piperidine;
 - 30 cis-3-(2-methoxybenzylamino)-2-(2-chlorophenyl)- piperidine;

- cis-3-(2-methoxybenzylamino)-2-(2-methylphenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-methoxyphenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-fluorophenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-chlorophenyl)- piperidine;
5 cis-3-(2-methoxybenzylamino)-2-phenylpiperidine;
cis-3-(2-methoxybenzylamino)-2-(3-methylphenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(4-fluorophenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-thienyl)-piperidine;
cis-3-(2-methoxybenzylamino)-2-phenylazacyclo-heptane;
10 3-(2-methoxybenzylamino)-4-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-5-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-6-methyl-2-phenylpiperidine;
(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5-carboethoxypent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
15 (2S,3S)-1-(6-hydroxy-hex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(4-hydroxy-4-phenylbut-1-yl)-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
(2S,3S)-1-(4-oxo-4-phenylbut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5,6-dihydroxyhex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
20 cis-3-(5-fluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
(2S,3S)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-[4-(4-fluorophenyl)-4-hydroxybut-1-yl]-3-(2-methoxybenzylamino)-2-phenylpiperidine;
25 cis-3-(2-methoxy-5-methylbenzylamino)-2-phenyl-piperidine;
(2S,3S)-1-(4-benzamidobut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
cis-3-(2-methoxynaphth-1-ylmethylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxybenzylamino)-1-(5-N-methyl-carboxamidopent-1-yl)-2-phenylpiperidine;


- (2S,3S)-1-(4-cyanobut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
 (2S,3S)-1-[4-(2-naphthamido)but-1-yl]-3-(2-methoxybenzylamino)-2-phenylpiperidine;
 (2S,3S)-1-(5-benzamidopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
 5 (2S,3S)-1-(5-aminopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
 (2S,3S)-3-(5-chloro-2-methoxybenzylamino)-2-phenylpiperidine;
 (2S,3S)-3-(2,5-dimethoxybenzylamino)-2-phenylpiperidine;
 cis-3-(3,5-difluoro-2-methoxybenzylamino)-2-phenylpiperidine;
 cis-3-(4,5-difluoro-2-methoxybenzylamino)-2-phenylpiperidine;
 10 cis-3-(2,5-dimethoxybenzylamino)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-2-phenylpiperidine;
 cis-3-(5-chloro-2-methoxybenzylamino)-1-(5,6-dihydroxyhex-1-yl)-2-phenylpiperidine;
 cis-1-(5,6-dihydroxyhex-1-yl)-3-(2,5-dimethoxybenzylamino)-2-phenylpiperidine;
 cis-2-phenyl-3-[2(prop-2-yloxy)benzylamino]piperidine;
 15 cis-3-(2,5-dimethoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine hydrochloride;
 cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine dihydrochloride;
 cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-chloro-phenyl)piperidine dihydrochloride;
 20 dihydrochloride; 3-(2-methoxybenzylamino)-2,4-diphenylpiperidine;
 cis-3-(2-methoxybenzylamino)-2-phenylpyrrolidine;
 (2S,3S)-3-(5-ethyl-2-methoxybenzyl)amino-2-phenylpiperidine;
 (2S,3S)-3-(5-n-butyl-2-methoxybenzyl)amino-2-phenylpiperidine;
 (2S,3S)-3-(2-methoxy-5-n-propylbenzyl)amino-2-phenylpiperidine;
 25 (2S,3S)-3-(5-isopropyl-2-methoxybenzyl)amino-2-phenylpiperidine;
 (2S,3S)-3-(5-s-butyl-2-methoxybenzyl)amino-2-phenylpiperidine;
 (2S,3S)-3-(5-t-butyl-2-methoxybenzyl)amino-2-phenylpiperidine;
 (2S,3S)-3-(2-methoxy-5-phenylbenzyl)amino-2-phenylpiperidine;

- 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanamide;
- N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanesulfonamide;
- 5 (5-[(4,5-dimethylthiazol-2-yl)methylamino]-2-methoxybenzyl)-((2S,3S)-2-phenylpiperidin-3-yl)amine;
- {5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl}-((2S,3S)-2-phenylpiperidin-3-yl)amine;
- 10 4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)-4-trifluoromethoxyphenyl]-amide;
- 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanamide;
- 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isopropylamide;
- 15 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylamino-methyl)phenyl]-isopropylamide;
- 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isobutylamide;
- 20 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isobutylamide;
- (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- 25 (2S,3S)-N-(5-methyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (2S,3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- 30 (2S,3S)-N-(5-sec-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;


- (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (3R,4S,5S,6S)-N,N-diethyl-5-(5-isopropyl-2-methoxy-benzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxamide;
- 5 (3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxamide;
- (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 10 (3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenyl-methyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 15 (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 20 (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxy-benzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 25 (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 30 (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;

- (3R,4S,5S,6S)-5-(2-methoxy-5-methylthiobenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 5 (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 10 (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 15 (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid; and
- 20 (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid; or pharmaceutically acceptable salts thereof.
5. The method of claim 1, wherein the NK-1 receptor antagonist is a compound of
- 25 Formula 1, Formula 2, or a pharmaceutically acceptable salt thereof.

-28-



Formula 1



Formula 2

- 5 6. The use of an NK-1 receptor antagonist to prepare a medicinal composition to treat abnormal anxiety behavior in companion animals.
7. A method of screening a test compound to determine anxiolytic activity in dogs comprising (a) selecting a dog exhibiting an anxiety behavior; (b) administering the test compound to the dog; (c) separating the dog from views of other dogs and of humans; (d) measuring a first duration of time, the first duration of time being the time within a separation period of a fixed duration during which the anxiety behavior is exhibited; and (e) comparing the first duration of time with a second duration of time, wherein the second duration of time is the time within a separation period of the fixed duration that the anxiety behavior is exhibited in the dog when the dog has not received the test compound for at least forty-eight hours; wherein if the first duration of time is less than the second duration of time, the test compound is determined to have anxiolytic activity.
- 10
- 15

8. The method of claim 7 wherein the anxiety behavior is selected from the group consisting of vocalization, hyperactivity, destruction, abnormal sleep, abnormal feeding, abnormal drinking, abnormal grooming, abnormal elimination, abnormal fears and phobias, and socialization disorders.
- 5 9. A method of treating abnormal anxiety behavior in a companion animal, the method comprising evaluating the companion animal for the exhibition of an abnormal anxiety behavior, determining that the companion animal exhibits the abnormal anxiety behavior and thus is in need of treatment, and administering to the companion animal a therapeutically effective amount of an NK-1 receptor antagonist for a time sufficient
10 to reduce or eliminate the abnormal anxiety behavior.
10. The method of claim 9, wherein the abnormal anxiety behavior is selected from the group consisting of vocalization, hyperactivity, destruction, abnormal sleep, abnormal feeding, abnormal drinking, abnormal grooming, abnormal elimination, abnormal fears and phobias, and socialization disorders.
- 15 11. The method of claim 9, wherein the companion animal is selected from the group consisting of dogs, cats, and horses.
12. The method of claim 9, wherein the NK-1 receptor antagonist is selected from the group consisting of:
 - (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine;
 - (2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine;
 - (2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine;
 - (2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
 - (2S,3S)-3-(5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
 - 25 2-(diphenylmethyl)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-1-azabicyclo[2.2.2]octan-3-amine;
 - (2S,3S)-3-[5-chloro-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
 - (2S,3S)-3-(5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
 - (2S,3S)-3-(2-isopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
 - 30 (2S,3S)-3-(2-difluoromethoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
 - (2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxybenzyl)-aminopiperidine];
 - (2S,3S)-2-phenyl-3-(2-trifluoromethoxybenzyl)]aminopi-peridine;

- cis-3-(2-chlorobenzylamino)-2-phenylpiperidine;
cis-3-(2-trifluoromethylbenzylamino)-2-phenyl- piperidine;
cis-3-(2-methoxybenzylamino)-2-(2-fluorophenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(2-chlorophenyl)- piperidine;
5 cis-3-(2-methoxybenzylamino)-2-(2-methylphenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-methoxyphenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-fluorophenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-chlorophenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-phenylpiperidine;
10 cis-3-(2-methoxybenzylamino)-2-(3-methylphenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(4-fluorophenyl)- piperidine;
cis-3-(2-methoxybenzylamino)-2-(3-thienyl)-piperidine;
cis-3-(2-methoxybenzylamino)-2-phenylazacyclo-heptane;
3-(2-methoxybenzylamino)-4-methyl-2-phenylpiperidine;
15 3-(2-methoxybenzylamino)-5-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-6-methyl-2-phenylpiperidine;
(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5-carboethoxypent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(6-hydroxy-hex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
20 (2S,3S)-1-(4-hydroxy-4-phenylbut-1-yl)-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
(2S,3S)-1-(4-oxo-4-phenylbut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5,6-dihydroxyhex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
cis-3-(5-fluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
(2S,3S)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-3-(2-methoxybenzylamino)-2-
25 phenylpiperidine;
(2S,3S)-1-[4-(4-fluorophenyl)-4-hydroxybut-1-yl]-3-(2-methoxybenzylamino)-2-
phenylpiperidine;
cis-3-(2-methoxy-5-methylbenzylamino)-2-phenyl-piperidine;


- (2S,3S)-1-(4-benzamidobut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
cis-3-(2-methoxynaphth-1-ylmethylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxybenzylamino)-1-(5-N-methyl-carboxamidopent-1-yl)-2-phenylpiperidine;
- 5 (2S,3S)-1-(4-cyanobut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-[4-(2-naphthamido)but-1-yl]-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5-benzamidopent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5-aminopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-3-(5-chloro-2-methoxybenzylamino)-2-phenyl-piperidine;
- 10 (2S,3S)-3-(2,5-dimethoxybenzylamino)-2-phenyl-piperidine;
cis-3-(3,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
cis-3-(4,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
cis-3-(2,5-dimethoxybenzylamino)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-2-phenylpiperidine;
- 15 cis-3-(5-chloro-2-methoxybenzylamino)-1-(5,6-dihydroxyhex-1-yl)-2-phenylpiperidine;
cis-1-(5,6-dihydroxyhex-1-yl)-3-(2,5-dimethoxy-benzylamino)-2-phenylpiperidine;
cis-2-phenyl-3-[2(prop-2-yloxy)benzylamino]piperidine;
cis-3-(2,5-dimethoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine hydrochloride;
- 20 cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine dihydrochloride;
cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-chloro-phenyl)piperidine dihydrochloride; 3-(2-methoxybenzylamino)-2,4-diphenylpiperidine;
cis-3-(2-methoxybenzylamino)-2-phenylpyrrolidine;
- 25 (2S,3S)-3-(5-ethyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-n-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-n-propylbenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-isopropyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-s-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;

- (2S,3S)-3-(5-*t*-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-phenylbenzyl)amino-2-phenyl-piperidine;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanamide;
5 N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanesulfonamide;
(5-[(4,5-dimethylthiazol-2-yl)methylamino]-2-methoxybenzyl)-((2S,3S)-2-phenylpiperidin-3-yl)amine;
(5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl)-((2S,3S)-2-phenylpiperidin-3-yl)amine;
10 4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)-4-trifluoromethoxyphenyl]-amide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-methanamide;
15 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isobutylamide;
20 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]-isobutylamide;
(2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
25 (2S,3S)-N-(5-*tert*-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-methyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
30 (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;


- (2S,3S)-N-(5-sec-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine;
- 5 (3R,4S,5S,6S)-N,N-diethyl-5-(5-isopropyl-2-methoxy-benzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxamide;
- (3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxamide;
- 10 (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 15 (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 20 (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxy-benzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 25 (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
- 30 (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;

- (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylthiobenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 5 (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 10 (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 15 (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid;
- 20 (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzyl-amino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid; and
- (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1-azabicyclo[2.2.2]octane-2-carboxylic acid; or pharmaceutically acceptable salts thereof.
- 25
13. The method of claim 9, wherein the NK-1 receptor antagonist is a compound of Formula 1, Formula 2, or a pharmaceutically acceptable salt thereof:

-35-



Formula 1



Formula 2

- 5 14. The method of claim 9, wherein the NK-1 receptor antagonist is administered once or twice daily for two to four months.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 02/02847

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/46 A61K31/4418 A61P25/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 15277 A (CARLSON EMMA JOANNE ;MERCK SHARP & DOHME (GB); RUPNIAK NADIA MELAN) 16 April 1998 (1998-04-16) page 59, line 16-20 page 60, line 3-6; page 61, line 16 - page 62, line 22; page 67, line 7 - page 69, line 17	1-14
X	US 6 156 749 A (RUPNIAK NADIA MELANIE) 5 December 2000 (2000-12-05) column 21, line 21-49; column 21, line 65 - column 22, line 22	1-14
X	EP 1 099 446 A (PFIZER PROD INC) 16 May 2001 (2001-05-16) '0088!-'0090!	1-14
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

10 October 2002

Date of mailing of the international search report

29/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo.nl
Fax: (+31-70) 340-3016

Authorized officer

Borst, M

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/IB 02/02847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SANTARELLI LUCA ET AL: "Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function."</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 4, 13 February 2001 (2001-02-13), pages 1912-1917, XP002214242</p> <p>February 13, 2001</p> <p>ISSN: 0027-8424</p> <p>page 1913, left-hand column, paragraph entitled "Behavioral Studies";</p> <p>page 1913-1916; paragraph entitled "Results and Discussion"</p>	1-14
X	<p>FUKUDA HIROYUKI ET AL: "The tachykinin NK1 receptor antagonist GR205171 abolishes the retching activity of neurons comprising the central pattern generator for vomiting in dogs."</p> <p>NEUROSCIENCE RESEARCH, vol. 33, no. 1, January 1999 (1999-01), pages 25-32, XP002216375</p> <p>ISSN: 0168-0102</p> <p>page 25-26, paragraph entitled "1. Introduction"</p>	1-14
X	<p>CULMAN J ET AL: "EFFECT OF TACHYKININ RECEPTOR INHIBITION IN THE BRAIN ON CARDIOVASCULAR AND BEHAVIORAL RESPONSES TO STRESS"</p> <p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 280, no. 1, January 1997 (1997-01), pages 238-246, XP000964757</p> <p>ISSN: 0022-3565</p> <p>table 1;</p> <p>page 245, right-hand column second full paragraph</p>	1-14
A	<p>WO 98 27086 A (HOECHST MARION ROUSSEL INC)</p> <p>25 June 1998 (1998-06-25)</p> <p>page 84, line 9 - page 85, line 27</p>	3,7,11
A	<p>WO 96 10568 A (MERCK & CO INC ;CHIANG YUAN CHING P (US); FINKE PAUL E (US); MACCO)</p> <p>11 April 1996 (1996-04-11)</p> <p>page 30, line 6 - page 31, line 29</p>	3,7,11
A	<p>WO 93 00331 A (PFIZER)</p> <p>7 January 1993 (1993-01-07)</p> <p>page 9, line 20 - page 12, line 4</p>	4,5,12,13
	<p>--- -/--</p>	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

page 2 of 3

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/IB 02/02847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SEWARD E M ET AL: "NEUROKININ RECEPTOR ANTAGONISTS" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 9, no. 5, 1999, pages 571-582, XP002214243 ISSN: 1354-3776 page 574, right-hand column, paragraph entitled "2.5 Psychiatric diseases"	1-15

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The present claims are directed to the therapeutic use of compounds, which are not defined in terms of their structure, but in terms of their function, ie their NK-1 receptor antagonising function. It is acknowledged that the application on file (cf. page 11, line 13-15) provides instructions in the form of testable criteria or experimental tests allowing the skilled person to recognise which concrete compounds fall within the functional definition and accordingly within the scope of the claim.

However, it should be kept in mind that for most of the chemical compounds known at the priority/filing date of the application on file the test for the claimed function has not yet been applied nor have the results thereof been published. Thus, the search can cover only those compounds for which the claimed function was known at the priority/filing date of the application on file and the compounds structurally defined in the application on file. Accordingly, it cannot be excluded that compounds which were tested for the claimed function after the priority/filing date of the application on file only and which were known at the priority/filing date of the application on file for the same therapeutic indication will become pertinent to the novelty of the claims on file.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/IB 02/02847

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-5 and 9-14 are directed to a method of treatment of the animal body, the search has been carried out and based on the alleged effects of the compound/composition (Rule 39.1(iv) PCT).
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/IB 02/02847

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9815277	A	16-04-1998	AU 726745 B2	16-11-2000
			AU 4567397 A	05-05-1998
			EP 0929303 A2	21-07-1999
			WO 9815277 A2	16-04-1998
			JP 2001502311 T	20-02-2001
			US 6319953 B1	20-11-2001
			US 2002042361 A1	11-04-2002
			US 6117855 A	12-09-2000
US 6156749	A	05-12-2000	NONE	
EP 1099446	A	16-05-2001	BR 0005319 A	17-07-2001
			EP 1099446 A2	16-05-2001
			JP 2001139490 A	22-05-2001
WO 9827086	A	25-06-1998	AT 214063 T	15-03-2002
			AU 723966 B2	07-09-2000
			AU 5160798 A	15-07-1998
			BR 9714057 A	09-05-2000
			DE 69710921 D1	11-04-2002
			DE 69710921 T2	19-09-2002
			DK 946548 T3	24-06-2002
			EP 0946548 A1	06-10-1999
			ES 2169881 T3	16-07-2002
			HU 0000315 A2	28-04-2001
			JP 2001506650 T	22-05-2001
			NO 993013 A	18-08-1999
			NZ 335975 A	24-11-2000
			PT 946548 T	28-06-2002
			SI 946548 T1	30-06-2002
			WO 9827086 A1	25-06-1998
			ZA 9711271 A	19-06-1998
WO 9610568	A	11-04-1996	US 5607936 A	04-03-1997
			AU 702832 B2	04-03-1999
			AU 3642995 A	26-04-1996
			CA 2199621 A1	11-04-1996
			EP 0783498 A1	16-07-1997
			JP 10508297 T	18-08-1998
			WO 9610568 A1	11-04-1996
WO 9300331	A	07-01-1993	AT 142199 T	15-09-1996
			AU 657967 B2	30-03-1995
			AU 1889392 A	25-01-1993
			BR 1100086 A3	25-07-2000
			BR 9206161 A	31-10-1995
			CA 2109613 A1	07-01-1993
			CN 1067655 A ,B	06-01-1993
			CZ 9203908 A3	13-04-1994
			CZ 290475 B6	17-07-2002
			DE 9290083 U1	17-02-1994
			DE 69213451 D1	10-10-1996
			DE 69213451 T2	09-01-1997
			DK 589924 T3	30-09-1996
			EG 20280 A	30-07-1998
			EP 0589924 A1	06-04-1994
			ES 2092113 T3	16-11-1996
			FI 935701 A	17-12-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/02847

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9300331 A		FI 990418 A	26-02-1999
		FI 990419 A	26-02-1999
		GR 3021411 T3	31-01-1997
		HK 1000247 A1	13-02-1998
		HU 67434 A2	28-04-1995
		HU 70499 A2	30-10-1995
		IE 921986 A1	30-12-1992
		JP 7110850 B	29-11-1995
		JP 6506473 T	21-07-1994
		KR 154882 B1	16-11-1998
		MX 9203018 A1	01-07-1993
		NO 934691 A ,B,	17-12-1993
		NZ 243230 A	24-06-1997
		PL 172054 B1	31-07-1997
		PL 170516 B1	31-12-1996
		PT 100606 A ,B	31-08-1993
		RU 2114848 C1	10-07-1998
		SK 390892 A3	13-09-1995
		WO 9300331 A1	07-01-1993
		US 5773450 A	30-06-1998
		US 5744480 A	28-04-1998
		ZA 9204528 A	20-12-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.